PDB rendering based on 2g47.
|External IDs||ChEMBL: GeneCards:|
|RNA expression pattern|
Known alternatively as insulysin or insulin protease, Insulin Degrading Enzyme (IDE) is a large zinc-binding protease of the M16A metalloprotease subfamily known to cleave multiple short polypeptides that vary considerably in sequence. IDE was first identified by its ability to degrade the B chain of the hormone insulin. This activity was observed over fifty years ago, though the enzyme specifically responsible for B chain cleavage was identified more recently. This discovery revealed considerable amino acid sequence similarity between IDE and the previously characterized bacterial protease pitrilysin, suggesting a common proteolytic mechanism. IDE, which migrates at 110 kDa during gel electrophoresis under denaturing conditions, has since been shown to have additional substrates, including the signaling peptides glucagon, TGF alpha, and β-endorphin.
Considerable interest in IDE has been stimulated due to the discovery that IDE can degrade amyloid beta (Aβ), a peptide implicated in the pathogenesis of Alzheimer's disease. The underlying cause or causes of the disease are unclear, though the primary neuropathology observed is the formation of amyloid plaques and neurofibrillary tangles. One hypothesized mechanism of disease, called the amyloid hypothesis, suggests that the causative agent is the hydrophobic peptide Aβ, which forms quaternary structures that, by an unclear mechanism, cause neuronal death. Aβ is a byproduct generated as the result of proteolytic processing of the amyloid precursor protein (APP) by proteases referred to as the β and γ secretases. The physiological role of this processing is unclear, though it may play a role in nervous system development.
Numerous in vitro and in vivo studies have shown correlations between IDE, Aβ degradation, and Alzheimer’s disease. Mice engineered to lack both alleles of the IDE gene exhibit a 50% decrease in Aβ degradation, resulting in cerebral accumulation of Aβ. Studies of genetically inherited forms of Alzheimer’s show reduction in both IDE expression and catalytic activity among affected individuals. Despite the evident role of IDE in disease, relatively little is known about its physiological functions. These may be diverse, as IDE has been localized to several locations, including the cytosol, peroxisomes, endosomes, proteasome complexes, and the surface of cerebrovascular endothelial cells.
Structure and function
Structural studies of IDE by Shen et al. have provided insight into the functional mechanisms of the protease. Reminiscent of the previously determined structure of the bacterial protease pitrilysin, the IDE crystal structure reveals defined N and C terminal units that form a proteolytic chamber containing the zinc-binding active site. In addition, it appears that IDE can exist in two conformations: an open conformation, in which substrates can access the active site, and a closed state, in which the active site is contained within the chamber formed by the two concave domains. Targeted mutations that prevent the closed conformation result in a 40-fold increase in catalytic activity. Based upon this observation, it has been proposed that a possible therapeutic approach to Alzheimer’s might involve shifting the conformational preference of IDE to the open state, and thus increasing Aβ degradation, preventing aggregation, and, ideally, preventing the neuronal loss that leads to disease symptoms.
Regulation of extracellular amyloid β-protein
Reports of IDE localized to the cytosol and peroxisomes  have raised concerns regarding how the protease could degrade endogenous Aβ. Several studies have detected insulin-degrading activity in the conditioned media of cultured cells, suggesting the permeability of the cell membrane and thus possible release of IDE from leaky cells. Qiu and colleagues revealed the presence of IDE in the extracellular media using antibodies to the enzyme. They also quantified levels of Aβ-degrading activity  using elution from column chromatography. Correlating the presence of IDE and Aβ-degrading activity in the conditioning medium confirmed that leaky membranes are responsible for extracellular IDE activity.
Potential role in the oligomerization of Aβ
Recent studies have observed that the oligomerization of synthetic Aβ was completely inhibited by the competitive IDE substrate, insulin. These findings suggest that IDE activity is capable of joining of several Aβ fragments together. Qui et al. hypothesized that the Aβ fragments generated by IDE can either enhance oligomerization of the Aβ peptide or can oligomerize themselves. It is also entirely possible that IDE could mediate the degradation and oligomerization of Aβ by independent actions that have yet to be investigated.
Despite the enormous attention dedicated to IDE the catalytic mechanism of this enzyme remain poorly understood. Studies present in literature explored many aspects concerning IDE, but none of them deals with the mechanistic details of the proteolysis performed by this enzyme. It is understood that IDE cleaves insulin B chain as well as amyloid β at several sites. Recently, Orazio and colleagues unveil how the cleavage of two peptides occurs by using the density functional theory at the active site of IDE (Scheme 1) to explore the catalytic mechanism of IDE; hence, they provide novel fundamental insights into the behavior of this enzyme.
The steps involved in the whole process are collected in Scheme 2.
The first step of the mechanism includes a zinc-bound hydroxide group performing a nucleophilic attack on a carbon substrate that materializes into the intermediate INT1. In this species, we can note that the zinc-bound hydroxide is completely transferred on the carbonyl carbon of substrate as a consequence of the Zn2+−OH bond breaking. In TS2, the Glu111 residue rotates to assume the right disposition to form two hydrogen bonds with the amide nitrogen and the −OH group linked to the carbon atom of substrate, thus behaving as hydrogen donor and acceptor, simultaneously. The formation of the second cited bond favors the re-establishment of the Zn2+−OH bond broken previously at the INT1 level. The nucleophilic addition and the protonation of peptide amide nitrogen is a very fast process that is believed to occur as a single step in the catalytic process. The final species on the path is the product PROD. As a consequence of transfer of the proton of Glu111 onto the amide nitrogen of substrate that occurred in TS3, the peptide N—C bond is broken.
A look at the whole reaction path indicates that the rate-determining step in this process is the nucleophilic addition that implies an expense of 17.2 kcal/mol. After this point, the catalytic event should proceed without particular obstacles.
|Glucose tolerance test||Normal|
|Auditory brainstem response||Normal|
|Peripheral blood lymphocytes||Abnormal|
|All tests and analysis from|
Model organisms have been used in the study of IDE function. A conditional knockout mouse line, called Idetm1a(EUCOMM)Wtsi was generated as part of the International Knockout Mouse Consortium program — a high-throughput mutagenesis project to generate and distribute animal models of disease to interested scientists.
Male and female animals underwent a standardized phenotypic screen to determine the effects of deletion. Twenty three tests were carried out on mutant mice and two significant abnormalities were observed. Homozygous mutant animals displayed abnormal drinking behavior, and males also had an increased NK cell number.
- "Entrez Gene: IDE insulin-degrading enzyme".
- Mirsky IA, Broh-Kahn RH (1949). "The inactivation of insulin by tissue extracts. I. The distribution and properties of insulin inactivating extracts (insulinase)". Arch Biochem. 20 (1): 1–9. PMID 18104389.
- Affholter JA, Fried VA, Roth RA (1988). "Human insulin-degrading enzyme shares structural and functional homologies with E. coli protease III". Science 242 (4884): 1415–8. doi:10.1126/science.3059494. PMID 3059494.
- Wang DS, Dickson DW, Malter JS (2006). "beta-Amyloid Degradation and Alzheimer's Disease". J. Biomed. Biotechnol. 2006 (3): 58406. doi:10.1155/JBB/2006/58406. PMC 1559921. PMID 17047308.
- Kurochkin IV, Goto S (1994). "Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme". FEBS Lett. 345 (1): 33–7. doi:10.1016/0014-5793(94)00387-4. PMID 8194595.
- Kerr ML, Small DH (2005). "Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development". J. Neurosci. Res. 80 (2): 151–9. doi:10.1002/jnr.20408. PMID 15672415.
- Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003). "Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo". Proc. Natl. Acad. Sci. U.S.A. 100 (7): 4162–7. doi:10.1073/pnas.0230450100. PMC 153065. PMID 12634421.
- Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S (2003). "Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele". Am. J. Pathol. 162 (1): 313–9. doi:10.1016/s0002-9440(10)63822-9. PMC 1851126. PMID 12507914.
- Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE (2007). "Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families". J. Biol. Chem. 282 (11): 7825–32. doi:10.1074/jbc.M609168200. PMID 17244626.
- Duckworth WC, Bennett RG, Hamel FG (1998). "Insulin degradation: progress and potential". Endocr. Rev. 19 (5): 608–24. doi:10.1210/er.19.5.608. PMID 9793760.
- Lynch JA, George AM, Eisenhauer PB, Conn K, Gao W, Carreras I, Wells JM, McKee A, Ullman MD, Fine RE (2006). "Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures". J. Neurosci. Res. 83 (7): 1262–70. doi:10.1002/jnr.20809. PMID 16511862.
- Shen Y, Joachimiak A, Rosner MR, Tang WJ (2006). "Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism". Nature 443 (7113): 870–4. doi:10.1038/nature05143. PMC 3366509. PMID 17051221.
- Authier F., Bergeron J. J., Ou W. J., Rachubinski R. A., Posner B. I., Walton P. A. (1995). "Insulin-degrading enzyme". Proc. Natl. Acad. Sci. U.S.A. 92 (9): 3859–63. doi:10.1073/pnas.92.9.3859. PMC 42061. PMID 7731996.
- Roth R. A., Mesirow M. L., Cassell D. J., Yokono K., Baba S. (1985). "Characterization of an insulin degrading enzyme from cultured human lymphocytes". Diabetes Res. Clin. Pract. 1 (1): 31–39. doi:10.1016/S0168-8227(85)80026-7. PMID 3915257.
- Semple J. W., Lang Y., Speck E. R., Delovitch T. L. (1995). "Processing and presentation of insulin. III. Insulin degrading enzyme: a neutral metalloendoproteinase that is non-homologous to classical endoproteinases mediates the processing of insulin epitopes for helper T cells". Int. Immunol. 4 (10): 1161–7. doi:10.1093/intimm/4.10.1161. PMID 1283335.
- Wei Qiao Qiu, Dominic M. Walsh, Zhen Ye, Konstantinos Vekrellis, Jimin Zhang, Marcia B. Podlisny, Marsha Rich Rosner‡, Afshin Safavi§, Louis B. Hersh§ and Dennis J. Selkoe (1998). "Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation". The Journal of Biological Chemistry 273 (49): 32730–8. doi:10.1074/jbc.273.49.32730. PMID 9830016.
- Song, E.-S., Juliano, A. M., Juliano, L. and Hersh, L. B.. (2003). "ATP Effects on Insulin-degrading Enzyme Are Mediated Primarily through Its Triphosphate Moiety". J. Biol. Chem. 278 (52): 54216–20. doi:10.1074/jbc.M411177200. PMID 15494400.
- Song, E.-S., Daily, A., Fried, M. G., Juliano, A. M., Juliano, L. and Hersh, L. B.. (2005). "Mutation of Active Site Residues of Insulin-degrading Enzyme Alters Allosteric Interactions". J. Biol. Chem. 280 (18): 17701–6. doi:10.1074/jbc.M501896200. PMID 15749695.
- Ciaccio, C., Tundo, G. R., Grasso, G., Spoto, G., Marasco, D., Ruvo, M., Gioia, M., Rizzarelli, E. and Coletta, M. J. (2008). "Somatostatin: A Novel Substrate and a Modulator of Insulin-Degrading Enzyme Activity". Mol. Biol. 385 (5): 1556–67. doi:10.1016/j.jmb.2008.11.025. PMID 19073193.
- Grasso, G., Rizzarelli, E. and Spoto, G. (2009). "The proteolytic activity of insulin-degrading enzyme: a mass spectrometry study". J. Mass Spectrom. 44 (5): 735–41. doi:10.1002/jms.1550. PMID 19127548.
- Alper, B. J. and Schmidt, W. K.. (2009). "A capillary electrophoresis method for evaluation of Abeta proteolysis in vitro". J. Neurosci. Methods. 178 (1): 40–5. doi:10.1016/j.jneumeth.2008.11.010. PMC 2931793. PMID 19071160.
- Evin, G. and Weidemann, A. (2002). "Possible role of amyloid-beta, adenine nucleotide translocase and cyclophilin-D interaction in mitochondrial dysfunction of Alzheimer's disease". Peptides 23 (10): 3859–3863. PMC 2737500. PMID 19759867.
- Neant-Fery, M., Garcia-Ordoez, R. D., Logan, T. P., Selkoe, D. J., Li, L., Reinstatler, L. and Leissring, M. A. (2008). "Molecular basis for the thiol sensitivity of insulin-degrading enzyme". Proc. Natl. Acad. Sci. U.S.A. 105 (28): 9582–7. doi:10.1073/pnas.0801261105. PMC 2474492. PMID 18621727.
- Orazio, A., Marino, T. Russo, N. and Toscano, M. (2009). "Human Insulin-Degrading Enzyme Working Mechanism". J. Am. Chem. Soc. 41 (41): 14804–11. doi:10.1021/ja9037142.
- Leopoldini M, Russo N, Toscano M (August 2009). "Determination of the catalytic pathway of a manganese arginase enzyme through density functional investigation". Chemistry 15 (32): 8026–36. doi:10.1002/chem.200802252. PMID 19288480.
- Hersh, L. B. (2006). "The insulysin (insulin degrading enzyme) enigma". Cell. Mol. Life Sci. 63 (21): 2432–34. doi:10.1007/s00018-006-6238-9. PMID 16952049.
- "Dysmorphology data for Ide". Wellcome Trust Sanger Institute.
- "Peripheral blood lymphocytes data for Ide". Wellcome Trust Sanger Institute.
- "Salmonella infection data for Ide". Wellcome Trust Sanger Institute.
- "Citrobacter infection data for Ide". Wellcome Trust Sanger Institute.
- Gerdin AK (2010). "The Sanger Mouse Genetics Programme: High throughput characterisation of knockout mice". Acta Ophthalmologica 88: 925–7. doi:10.1111/j.1755-3768.2010.4142.x.
- Mouse Resources Portal, Wellcome Trust Sanger Institute.
- "International Knockout Mouse Consortium".
- "Mouse Genome Informatics".
- Skarnes, W. C.; Rosen, B.; West, A. P.; Koutsourakis, M.; Bushell, W.; Iyer, V.; Mujica, A. O.; Thomas, M.; Harrow, J.; Cox, T.; Jackson, D.; Severin, J.; Biggs, P.; Fu, J.; Nefedov, M.; De Jong, P. J.; Stewart, A. F.; Bradley, A. (2011). "A conditional knockout resource for the genome-wide study of mouse gene function". Nature 474 (7351): 337–342. doi:10.1038/nature10163. PMC 3572410. PMID 21677750.
- Dolgin E (2011). "Mouse library set to be knockout". Nature 474 (7351): 262–3. doi:10.1038/474262a. PMID 21677718.
- Collins FS, Rossant J, Wurst W (2007). "A Mouse for All Reasons". Cell 128 (1): 9–13. doi:10.1016/j.cell.2006.12.018. PMID 17218247.
- van der Weyden L, White JK, Adams DJ, Logan DW (2011). "The mouse genetics toolkit: revealing function and mechanism.". Genome Biol 12 (6): 224. doi:10.1186/gb-2011-12-6-224. PMC 3218837. PMID 21722353.
- The MEROPS online database for peptidases and their inhibitors: M16.002
- Insulin-Degrading Enzyme at the US National Library of Medicine Medical Subject Headings (MeSH)